80 related articles for article (PubMed ID: 15148832)
1. [Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].
Kimata H; Teshigahara O; Nishiyama Y; Nakao A
Nihon Rinsho; 2004 May; 62(5):987-93. PubMed ID: 15148832
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
Kimata H; Imai T; Kikumori T; Teshigahara O; Nagasaka T; Goshima F; Nishiyama Y; Nakao A
Ann Surg Oncol; 2006 Aug; 13(8):1078-84. PubMed ID: 16865590
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
6. Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.
Nakao A; Takeda S; Shimoyama S; Kasuya H; Kimata H; Teshigahara O; Sawaki M; Kikumori T; Kodera Y; Nagasaka T; Goshima F; Nishiyama Y; Imai T
Curr Cancer Drug Targets; 2007 Mar; 7(2):169-74. PubMed ID: 17346108
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
Kimata H; Takakuwa H; Goshima F; Teshigahara O; Nakao A; Kurata T; Sata T; Nishiyama Y
Hepatogastroenterology; 2003; 50(52):961-6. PubMed ID: 12845959
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice.
Takakuwa H; Goshima F; Nozawa N; Yoshikawa T; Kimata H; Nakao A; Nawa A; Kurata T; Sata T; Nishiyama Y
Arch Virol; 2003 Apr; 148(4):813-25. PubMed ID: 12664303
[TBL] [Abstract][Full Text] [Related]
10. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.
Kasuya H; Kodera Y; Nakao A; Yamamura K; Gewen T; Zhiwen W; Hotta Y; Yamada S; Fujii T; Fukuda S; Tsurumaru N; Kuwahara T; Kikumori T; Koide Y; Fujimoto Y; Nakashima T; Hirooka Y; Shiku H; Tanaka M; Takesako K; Kondo T; Aleksic B; Kawashima H; Goto H; Nishiyama Y
Hepatogastroenterology; 2014 May; 61(131):599-605. PubMed ID: 26176043
[TBL] [Abstract][Full Text] [Related]
11. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer.
Sahin TT; Kasuya H; Nomura N; Shikano T; Yamamura K; Gewen T; Kanzaki A; Fujii T; Sugae T; Imai T; Nomoto S; Takeda S; Sugimoto H; Kikumori T; Kodera Y; Nishiyama Y; Nakao A
Cancer Gene Ther; 2012 Apr; 19(4):229-37. PubMed ID: 22193629
[TBL] [Abstract][Full Text] [Related]
12. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.
Fujimoto Y; Mizuno T; Sugiura S; Goshima F; Kohno S; Nakashima T; Nishiyama Y
Acta Otolaryngol; 2006 Oct; 126(10):1115-7. PubMed ID: 16923721
[TBL] [Abstract][Full Text] [Related]
15. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
Shimoyama S; Goshima F; Teshigahara O; Kasuya H; Kodera Y; Nakao A; Nishiyama Y
Hepatogastroenterology; 2007 Jun; 54(76):1038-42. PubMed ID: 17629034
[TBL] [Abstract][Full Text] [Related]
16. [Oncolytic virotherapy using replication-competent herpes simplex viruses].
Nishiyama Y; Goshima F
Uirusu; 2007 Jun; 57(1):57-65. PubMed ID: 18040155
[TBL] [Abstract][Full Text] [Related]
17. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
19. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
